CRNX
Price
$27.40
Change
+$0.55 (+2.05%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
2.53B
87 days until earnings call
VRNA
Price
$105.25
Change
-$0.03 (-0.03%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
9.07B
Earnings call today
Interact to see
Advertisement

CRNX vs VRNA

Header iconCRNX vs VRNA Comparison
Open Charts CRNX vs VRNABanner chart's image
Crinetics Pharmaceuticals
Price$27.40
Change+$0.55 (+2.05%)
Volume$15.26K
Capitalization2.53B
Verona Pharma
Price$105.25
Change-$0.03 (-0.03%)
Volume$18.93K
Capitalization9.07B
CRNX vs VRNA Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. VRNA commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and VRNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (CRNX: $26.85 vs. VRNA: $105.28)
Brand notoriety: CRNX and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 270% vs. VRNA: 14%
Market capitalization -- CRNX: $2.53B vs. VRNA: $9.07B
CRNX [@Biotechnology] is valued at $2.53B. VRNA’s [@Biotechnology] market capitalization is $9.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, VRNA is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 3 TA indicator(s) are bullish while VRNA’s TA Score has 2 bullish TA indicator(s).

  • CRNX’s TA Score: 3 bullish, 7 bearish.
  • VRNA’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, both CRNX and VRNA are a bad buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -3.56% price change this week, while VRNA (@Biotechnology) price change was +0.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

VRNA is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($9.07B) has a higher market cap than CRNX($2.53B). VRNA YTD gains are higher at: 126.701 vs. CRNX (-47.487). VRNA has higher annual earnings (EBITDA): -121.41M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. VRNA (401M). CRNX has less debt than VRNA: CRNX (50.8M) vs VRNA (244M). VRNA has higher revenues than CRNX: VRNA (119M) vs CRNX (760K).
CRNXVRNACRNX / VRNA
Capitalization2.53B9.07B28%
EBITDA-373.49M-121.41M308%
Gain YTD-47.487126.701-37%
P/E RatioN/AN/A-
Revenue760K119M1%
Total Cash1.27B401M318%
Total Debt50.8M244M21%
FUNDAMENTALS RATINGS
CRNX vs VRNA: Fundamental Ratings
CRNX
VRNA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
722
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
8835
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRNA's Valuation (83) in the Pharmaceuticals Other industry is in the same range as CRNX (86) in the Pharmaceuticals Major industry. This means that VRNA’s stock grew similarly to CRNX’s over the last 12 months.

VRNA's Profit vs Risk Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for CRNX (72) in the Pharmaceuticals Major industry. This means that VRNA’s stock grew significantly faster than CRNX’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as VRNA (98) in the Pharmaceuticals Other industry. This means that CRNX’s stock grew similarly to VRNA’s over the last 12 months.

VRNA's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRNX (88) in the Pharmaceuticals Major industry. This means that VRNA’s stock grew somewhat faster than CRNX’s over the last 12 months.

VRNA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that VRNA’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXVRNA
RSI
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
70%
Momentum
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
78%
MACD
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 26 days ago
77%
Bullish Trend 18 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 6 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
80%
Aroon
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IRLCX43.800.41
+0.94%
Voya Russell Large Cap Index Port S
FZANX49.930.32
+0.65%
Fidelity Advisor New Insights Z
GSIKX21.110.11
+0.52%
Goldman Sachs International Eq Inc Instl
RYCHX172.200.83
+0.48%
Rydex Technology C
WOOSX18.11-0.06
-0.33%
JPMorgan SMID Cap Equity R6

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-3.69%
XNCR - CRNX
61%
Loosely correlated
-1.23%
IDYA - CRNX
58%
Loosely correlated
+3.08%
RVMD - CRNX
56%
Loosely correlated
+0.17%
NRIX - CRNX
55%
Loosely correlated
-2.28%
SYRE - CRNX
55%
Loosely correlated
N/A
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with RYTM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
-0.11%
RYTM - VRNA
45%
Loosely correlated
-0.54%
ZYME - VRNA
42%
Loosely correlated
-1.15%
IRON - VRNA
42%
Loosely correlated
+1.68%
CRNX - VRNA
41%
Loosely correlated
-3.69%
ROIV - VRNA
41%
Loosely correlated
-0.52%
More